Sebia

#Health / Well-being #Scientific Instrumentation

• In vitro diagnostics
• Clinical biochemistry
• Electrophoresis
• Instruments
• Reagents
• Monoclonal gammopathies, Hemoglobinopathies, Diabetes
• Chronic alcohol abuse

BACKGROUND
Since its incorporation 50 years ago, SEBIA has become a global leader in innovative electrophoretic in vitro diagnostic systems and particularly in the field of capillary electrophoresis.
DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY
Electrophoresis consists in the use of an electrical field to separate the proteins contained in biological samples. The most recent capillary electrophoresis technique is applied in the dedicated automated systems: the CAPILLARYS range (CAPILLARYS 2 Flex Piercing, CAPILLARYS 2 Neonat Fast and Capillarys 3) and MINICAP Flex Piercing.

The HYDRASYS range (ASSIST, HYDRASYS 2 SCAN, HYDRASYS 2 SCAN FOCUSING) utilizes an agarose gel as a support.

The electrophoresis technique is a leading technology in the diagnosis of immune system diseases such as myeloma, hemoglobin abnormalities, HbA1c and the detection of other protein markers.
CUSTOMER REFERENCES / COLLABORATIONS / HIGHLIGHTS
SEBIA’s R&D efforts are delivering results in two fields:

• The development of fully automated high-throughput systems with networking capabilities with the powerful PHORESIS CORE software, plus a full range of diagnostic tests: proteins, lipoproteins, hemoglobin, HbA1c. SEBIA recently introduced the Capillarys 3 program, including several types of complementary instruments (Capillarys 3 TERA and TERA M.C) offering to all kind of laboratories the modularity and flexibility required in today’s global organization of lab work.
• SEBIA products are available in 120 countries, through a network of 14 subsidiaries and representative offices and a broad network of distributors.

Moreover SEBIA offers high quality products and services throughout the world.
COLLABORATIONS SOUGHT
Sebia maintains close links with the medical community, including university labs associated with its research work and disease specialists developing applications. Sebia has also started collaborations with several associations involved in research projects that bring information and support to patients suffering from myeloma and to their families.

• Further Information

  Annual turnover: €250M
  > 700 staff members worldwide
  Strengths:
  World leader in the IVD field using the electrophoresis technology. Strong innovation capacity. Number 1 company for the diagnosis of monoclonal gammopathies. Major player in the fields of hemoglobin disorders and diabetes through the HbA1c test. High-level scientific and technical support. Education.
  Innovation assets:
  50 years of experience in electrophoresis technology. A renowned company worldwide for the diagnosis of multiple myeloma. Fully integrated company, with all the departments concentrated in Lisses (R&D, manufacturing, regulatory affairs, quality assurance, marketing, commercial, after sales service, scientific assistance and logistics).
  Other facts:
  Export represents more than 85% of Sebia’s sales turnover.